BOSTON--(BUSINESS WIRE)--Mar. 16, 2017--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the Company will host a
conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m.
Eastern Time to discuss corporate updates and financial results for the
fourth quarter and year ended December 31, 2016.
The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or
(315) 625-3226 (international), and entering passcode 89196444. To
access the live webcast, or the subsequent archived recording, please
use either the following link: http://edge.media-server.com/m/p/hazmwk76
or visit the investors section of the Verastem website at www.verastem.com.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has
successfully met its primary endpoint in a Phase 2 study and is
currently being evaluated in a Phase 3 clinical trial in patients with
chronic lymphocytic leukemia (CLL). Other clinical product candidates
include focal adhesion kinase (FAK) inhibitors defactinib and VS-4718,
and dual PI3K/mTOR inhibitor VS-5584. Defactinib is currently being
evaluated in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic, ovarian and non-small cell lung cancer, and
mesothelioma. Verastem’s product candidates seek to treat cancer by
modulating the local tumor microenvironment, enhancing anti-tumor
immunity and reducing cancer stem cells. For more information, please
View source version on businesswire.com: http://www.businesswire.com/news/home/20170316005445/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214